What is the recommended Stereotactic Radiosurgery (SRS) dose for a patient with a 2.5 cubic centimeter (cc) brain metastasis (brain mets)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 19, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Stereotactic Radiosurgery Dose for 2.5 cc Brain Metastasis

For a 2.5 cc brain metastasis, the recommended single-fraction SRS dose is 18 Gy, based on established dose-volume relationships that balance local control with toxicity risk. 1

Dose Selection Algorithm

The appropriate SRS dose for your 2.5 cc lesion follows a volume-based approach:

  • Lesions <2 cm diameter (typically <4 cc): 18-24 Gy single fraction is recommended 1
  • Your 2.5 cc lesion falls within this range, making 18 Gy the standard dose 2, 1
  • Lesions 2.5 cm or less: Historical data supports 16 Gy as effective, though modern practice favors 18 Gy for optimal control 2

Evidence Supporting This Dose

The dose recommendation is derived from RTOG 90-05 protocol, which established maximum marginal doses based on tumor volume: 24 Gy for lesions <2 cm, 18 Gy for lesions 2-3 cm, and 15 Gy for lesions 3-4 cm 2. Your 2.5 cc lesion (approximately 1.7 cm diameter if spherical) positions it in the 18-24 Gy range, with 18 Gy being the conservative and widely accepted choice 1.

Multiple guidelines confirm that minimum doses of ≥18 Gy provide optimal local control, with reported control rates of 81-98% for lung cancer metastases and 90-94% for breast cancer metastases 3. The International Stereotactic Radiosurgery Society practice guideline specifically notes that lesions ≤2.5 cm can be treated with single-fraction doses in this range 2.

Critical Considerations That May Modify Dose

Location relative to critical structures is the primary factor that could necessitate dose reduction or fractionation:

  • If your lesion is near the optic apparatus, brainstem, or other radiosensitive structures, consider fractionated SRS (25 Gy in 5 fractions or 27 Gy in 3 fractions) instead of single-fraction treatment 1
  • For lesions in non-eloquent locations away from critical structures, proceed with 18 Gy single fraction 2, 1

Prescription isodose line should typically be 50% (range 20-90%) for optimal dose conformality 4. This means the maximum dose at the center of the lesion will be approximately 36 Gy when prescribing 18 Gy to the margin.

Alternative Fractionation Approach

If single-fraction SRS is contraindicated due to location or patient factors, fractionated stereotactic radiosurgery delivers 25 Gy in 5 fractions as the most common alternative schedule 1. This approach:

  • Reduces the risk of radiation necrosis for larger volumes 2
  • Allows safer treatment near critical structures 1
  • Provides equivalent local control with potentially lower toxicity 2

Common Pitfalls to Avoid

Do not reduce the dose below 18 Gy for a 2.5 cc lesion in a non-critical location, as this compromises local control 3. Studies demonstrate that doses <18 Gy result in inferior outcomes, with local control rates dropping significantly 2.

Do not automatically add whole brain radiation therapy (WBRT) to SRS for this single lesion, as WBRT causes significant neurocognitive decline without survival benefit 2. SRS alone is the preferred approach for limited metastases 2.

Ensure adequate margins: Use 0-2 mm PTV margins for intact metastases to minimize normal brain exposure while accounting for setup uncertainty 4. Larger margins are unnecessary and increase toxicity risk.

Expected Outcomes

With 18 Gy single-fraction SRS to a 2.5 cc brain metastasis, you can expect:

  • Local control rates of 82-96% at 1 year, depending on histology 2, 3
  • Median survival of 10.6 months with SRS alone for favorable prognosis patients 2
  • Radiation necrosis risk of 5-10% with appropriate dosing 2
  • Preservation of neurocognitive function compared to WBRT 2

References

Guideline

Dose Constraints for Stereotactic Radiosurgery

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Stereotactic Radiosurgery for Brain Metastases

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.